ArticleJournal of global health2026
Strengthening healthcare systems to prevent antimicrobial resistance in LMICs: it is time to act.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Best practices in sample management & pre-analytical quality control: overcoming challenges in resource-limited laboratory settings.Tropical medicine and health · 2026Review
- Editorial: New Target Product Profiles From the WHO as Climate Change, Global Population Migration, and Conflict Drive Antimicrobial Resistance.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Antimicrobial-Resistant Infections in the Eastern Mediterranean Region (EMR): Burden, Mortality Trends, and Progress Toward AMR Reduction Milestones (2013-2023).Health services insights · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses a rapidly growing threat to global health, with low- and middle-income countries (LMICs) bearing a disproportionate burden. These LMICs face challenges such as weak health system governance, limited diagnostic capacity, undertrained workforces, and poorly regulated antibiotic markets that drive inappropriate antimicrobial use and accelerate AMR. In settings where over-the-counter antibiotic sales remain widespread and empirical treatment is a routine, AMR undermines treatment effectiveness and increases preventable morbidity and mortality. If left unaddressed, AMR is predicted to result in 10 million deaths per year by 2050. Combating AMR in LMICs requires a comprehensive approach: strengthening healthcare systems, enforcing prescription-only policies, raising public health awareness, and fostering collaboration between governments, non-governmental organisations, and international stakeholders. Priority actions include regulating informal pharmaceutical markets, embedding antimicrobial stewardship within primary care, expanding access to basic diagnostics, and using digital health tools to support prescribers and patients. Drawing on regional LMIC experiences, this viewpoint highlights practical pathways for aligning health system reform with AMR containment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.